Getein H-FABP Fast Test Kit is used in the early diagnosis of AMI and pulmonary embolism, and monitoring of chronic heart failure.
H-FABP Fast Test Kit
(Immunofluorescence Assay)
H-FABP Fast Test Kit (Immunofluorescence Assay) is intended for in vitro quantitative determination of Heart-type Fatty Acid Binding Protein (H-FABP) in serum, plasma or whole blood. This test is used in the early diagnosis of AMI and pulmonary embolism, and monitoring of chronic heart failure.
About H-FABP
H-FABP (Heart-type Fatty Acid Binding Protein) that finds in abundance in cardiomyocytes is one of the Fatty acid-binding proteins (FABPs). The molecular weight of H-FABP is about 15 kDa, the combination of their low molecular weight and cytoplasmic location means that H-FABP proteins are released very rapidly following Acute Myocardial Infarction (AMI). H-FABP has been repeatedly shown to a highly sensitive early rise biomarker across the full spectrum of ACS, detectable as early as 30 minutes following the onset of an ischemic episode.
Contents
1. For Getein1100
Package specifications: 25 tests/box, 10 tests/box
1) H-FABP test card in a sealed pouch with desiccant
2) Disposable pipet
3) User manual: 1 piece/box
4) SD/RFID card: 1 piece/box
5) Whole blood buffer: 1 bottle/box
2. For Getein1600
Package specifications: 2×24 tests/kit, 2×48 tests/kit
1) Sealed cartridge with 24/48 Getein H-FABP test cards
2) User manual: 1 piece/box
Materials required for Getein1600:
1) Sample diluent: 1 bottle/box
2) Box with pipette tips: 96 tips/box
3) Mixing plate: 1 piece/box
Note: Do not mix or interchange different batches of kits.
Specifications
Test Item |
Sample |
Detection Range |
Storage Condition |
H-FABP |
P/S/WB |
1.0 ng/ml~120.0 ng/ml |
4-30℃ |
Method |
Test Time |
Cut-off Value |
Shelf Life |
Immunofluorescence Assay |
3 min |
6.36 ng/ml |
24 months |
Applicable Device
Getein1100 Immunofluorescence Quantitative Analyzer
Getein1600 Immunofluorescence Quantitative Analyzer
Clinical Application
1. As an aid in the diagnosis of various causes of chest pain;
2. As an aid in the diagnosis of myocardial injury;
3. As an aid in the early diagnosis and risk classification of ACS.
4. As an aid in the monitoring and prognostic assessment of clinical treatment.